Adicet Bio director granted 4,200 stock options

Adicet Bio director Steve Dubin received a new stock option grant covering 4,200 shares of common stock.

Rhea-AI Filing Summary

Adicet Bio director Steve Dubin received a new stock option grant covering 4,200 shares of common stock. The option has an exercise price of $8.10 per share and expires on June 20, 2036. It was awarded as compensation rather than through an open-market purchase or sale.

The option will vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, as long as Dubin continues serving on the board. Following this grant, he holds 4,200 option shares related to this award.

Insider Trade Summary

Grant/Award: 4,200 shares

Grant/Award 1 txn

Insider DUBIN STEVE

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	4,200	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 4,200 contracts (Direct)

Footnotes (1)

1. F1. These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.

Key Figures

Option grant size: 4,200 shares Exercise price: $8.10 per share Expiration date: June 20, 2036 +1 more

4 metrics

Option grant size 4,200 shares Underlying common stock in new option grant

Exercise price $8.10 per share Strike price of granted stock options

Expiration date June 20, 2036 Option term end for granted award

Post-grant option holdings 4,200 shares Total shares subject to this option after grant

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vest in full, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "8.1000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-20T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest in full financial

"These shares shall vest in full on the earlier to occur of"

annual meeting of stockholders financial

"the date of the next annual meeting of stockholders following the grant date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Adicet Bio (ACET) report for Steve Dubin?

Adicet Bio reported a grant of stock options to director Steve Dubin for 4,200 underlying common shares. The options were awarded at an exercise price of $8.10 per share as part of his board compensation, not through an open-market trade.

What are the key terms of Steve Dubin’s new Adicet Bio (ACET) stock options?

Steve Dubin received options to acquire 4,200 Adicet Bio common shares at $8.10 per share, expiring June 20, 2036. These options were granted for no cash cost at grant and represent a compensation-related award linked to his board service.

How and when do Steve Dubin’s Adicet Bio (ACET) options vest?

The options vest in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting. Vesting is conditioned on Steve Dubin’s continued service on Adicet Bio’s board of directors through that vesting date under the grant terms.

Did Steve Dubin buy or sell Adicet Bio (ACET) shares in the market?

No open-market buy or sell was reported; the filing shows a compensation grant coded as an acquisition. Steve Dubin received stock options for 4,200 shares, rather than purchasing or selling existing common stock on the public market.

What is Steve Dubin’s position in the newly granted Adicet Bio (ACET) options?

Following the grant, Steve Dubin holds 4,200 option shares associated with this award. These options give him the right to buy Adicet Bio common stock at $8.10 per share before their June 20, 2036 expiration, once they are fully vested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 04:31 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DUBIN STEVE

(Last) (First) (Middle)

C/O ADICET BIO, INC.

131 DARTMOUTH STREET, FLOOR 3

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adicet Bio, Inc. [ ACET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.1	06/21/2026		A		4,200		(1)	06/20/2036	Common Stock	4,200	$0	4,200	D

Explanation of Responses:

1. These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.

	/s/ Nick Harvey, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)